RESUMO
BACKGROUND: Previous studies indicate an association between tobacco smoking and infectious diseases. However, large population-based follow-up studies including both accurate measurements of smoking behaviour and confounders and a reliable register-based follow-up of infections are lacking. OBJECTIVE: To examine the effect of smoking on use of antibacterials as an indicator of infections among working-aged population. METHODS: The participants of the population-based Health and Social Support Study (24,283 working-aged Finns) were followed up for 9 years. Information on smoking behaviour and confounders was obtained from a questionnaire in 1998. Number of antibacterial purchases was obtained from the National-Drug-Prescription-Register. The association between smoking and use of antibacterials was analysed using multinomial regression models. RESULTS: A graded association between lifetime smoking as measured by pack-years and use of antibacterials was found. Compared with never-smokers, the age-adjusted OR for multiple use of antibacterials among smokers with 12 or more pack-years was 2.32 (95% CI 1.91 to 2.82) in women and 1.45 (95% CI 1.23 to 1.71) in men. The associations remained after adjustment for the following confounding factors: use of alcohol, body mass index, physical activity, socioeconomic status, hard physical work, life satisfaction, disability pension and dyspnoea. CONCLUSIONS: Smoking is associated with increased use of antibacterials. Infectious periods experienced by patients should be used as an opportunity to encourage smoking cessation.
Assuntos
Antibacterianos/uso terapêutico , Infecções/etiologia , Fumar , Adulto , Fatores de Confusão Epidemiológicos , Feminino , Finlândia , Seguimentos , Humanos , Infecções/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Razão de Chances , Adulto JovemRESUMO
BACKGROUND: Asthma leads to structural changes in the airways, including the modification of extracellular matrix proteins such as tenascin-C. The role of tenascin-C is unclear, but it might act as an early initiator of airway wall remodelling, as its expression is increased in the mouse and human airways during allergic inflammation. In this study, we examined whether Th1 or Th2 cells are important regulators of tenascin-C in experimental allergic asthma utilizing mice with impaired Th1 (STAT4-/-) or Th2 (STAT6-/-) immunity. METHODS: Balb/c wildtype (WT), STAT4-/- and STAT6-/- mice were sensitized with intraperitoneally injected ovalbumin (OVA) followed by OVA or PBS airway challenge. Airway hyperreactivity (AHR) was measured and samples were collected. Real time PCR and immunohistochemistry were used to study cytokines and differences in the expression of tenascin-C. Tenascin-C expression was measured in human fibroblasts after treatment with TNF-α and IFN-γ in vitro. RESULTS: OVA-challenged WT mice showed allergic inflammation and AHR in the airways along with increased expression of TNF-α, IFN-γ, IL-4 and tenascin-C in the lungs. OVA-challenged STAT4-/- mice exhibited elevated AHR and pulmonary eosinophilia. The mRNA expression of TNF-α and IFN-γ was low, but the expression of IL-4 was significantly elevated in these mice. OVA-challenged STAT6-/- mice had neither AHR nor pulmonary eosinophilia, but had increased expression of mRNA for TNF-α, IFN-γ and IL-4. The expression of tenascin-C in the lungs of OVA-challenged STAT4-/- mice was weaker than in those of OVA-challenged WT and STAT6-/- mice suggesting that TNF-α and IFN-γ may regulate tenascin-C expression in vivo. The stimulation of human fibroblasts with TNF-α and IFN-γ induced the expression of tenascin-C confirming our in vivo findings. CONCLUSIONS: Expression of tenascin-C is significantly attenuated in the airways of STAT4-/- mice, which may be due to the impaired secretion of TNF-α and IFN-γ in these mice.
Assuntos
Remodelação das Vias Aéreas , Asma/metabolismo , Pulmão/metabolismo , Fator de Transcrição STAT4/deficiência , Tenascina/metabolismo , Animais , Asma/genética , Asma/imunologia , Asma/fisiopatologia , Hiper-Reatividade Brônquica , Células Cultivadas , Modelos Animais de Doenças , Feminino , Fibroblastos/imunologia , Fibroblastos/metabolismo , Humanos , Interferon gama/metabolismo , Pulmão/imunologia , Pulmão/fisiopatologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Knockout , Ovalbumina , RNA Mensageiro/metabolismo , Fator de Transcrição STAT4/genética , Fator de Transcrição STAT6/deficiência , Fator de Transcrição STAT6/genética , Tenascina/genética , Células Th1/imunologia , Células Th2/imunologia , Fator de Necrose Tumoral alfa/metabolismo , Regulação para CimaRESUMO
Neuropeptide S receptor 1 (NPSR1, GPRA 154, GPRA) has been verified as a susceptibility gene for asthma and related phenotypes. The ligand for NPSR1, Neuropeptide S (NPS), activates signalling through NPSR1 and microarray analysis has identified Tenascin C (TNC) as a target gene of NPS-NPSR1 signalling. TNC has previously been implicated as a risk gene for asthma. We aimed therefore to study the genetic association of TNC in asthma- and allergy-related disorders as well as the biological and genetic interactions between NPSR1 and TNC. Regulation of TNC was investigated using NPS stimulated NPSR1 transfected cells. We genotyped 12 TNC SNPs in the cross-sectional PARSIFAL study (3113 children) and performed single SNP association, haplotype association and TNC and NPSR1 gene-gene interaction analyses. Our experimental results show NPS-dependent upregulation of TNC-mRNA. The genotyping results indicate single SNP and haplotype associations for several SNPs in TNC with the most significant association to rhinoconjunctivitis for a haplotype, with a frequency of 29% in cases (P = 0.0005). In asthma and atopic sensitization significant gene-gene interactions were found between TNC and NPSR1 SNPs, indicating that depending on the NPSR1 genotype, TNC can be associated with either an increased or a decreased risk of disease. We conclude that variations in TNC modifies, not only risk for asthma, but also for rhinoconjunctivitis. Furthermore, we show epistasis based on both a direct suggested regulatory effect and a genetic interaction between NPSR1 and TNC. These results suggest merging of previously independent pathways of importance in the development of asthma- and allergy-related traits.
Assuntos
Asma/genética , Hipersensibilidade/genética , Receptores Acoplados a Proteínas G/genética , Tenascina/genética , Alelos , Brônquios/metabolismo , Linhagem Celular , Criança , Conjuntivite Alérgica/genética , Epistasia Genética , Regulação da Expressão Gênica , Haplótipos , Humanos , Neuropeptídeos/metabolismo , Neuropeptídeos/farmacologia , Polimorfismo de Nucleotídeo Único , RNA Mensageiro/metabolismo , Receptores Acoplados a Proteínas G/agonistas , Receptores Acoplados a Proteínas G/metabolismo , Rinite/genéticaRESUMO
The neuropeptide S (NPS)-NPS receptor 1 (NPSR1) pathway has recently been implicated in the pathogenesis of asthma. The purpose of this study was to identify downstream gene targets regulated by NPSR1 upon NPS stimulation. A total of 104 genes were found significantly up-regulated and 42 down-regulated by microarray analysis 6 h after NPS administration. By Gene Ontology enrichment analysis, the categories 'cell proliferation', 'morphogenesis' and 'immune response' were among the most altered. A TMM microarray database comparison suggested a common co-regulated pathway, which includes JUN/FOS oncogene homologs, early growth response genes, nuclear receptor subfamily 4 members and dual specificity phosphatases. The expression of four up-regulated genes, matrix metallopeptidase 10 (MMP10), INHBA (activin A), interleukin 8 (IL8) and EPH receptor A2 (EPHA2), exhibited a significant NPS dose-response relationship as confirmed by quantitative reverse-transcriptase-PCR and for MMP10 by immunoassay. Immunohistochemical analyses revealed that MMP10 and TIMP metallopeptidase inhibitor 3 (TIMP3) were both strongly expressed in bronchial epithelium, and macrophages and eosinophils expressed MMP10 in asthmatic sputum samples. Because remodeling of airway epithelium is a feature of chronic asthma, the up-regulation of MMP10 and TIMP3 by NPS-NPSR1 signaling may be of relevance in the pathogenesis of asthma.
Assuntos
Neuropeptídeos/genética , Neuropeptídeos/metabolismo , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/metabolismo , Apoptose , Asma/etiologia , Asma/genética , Asma/metabolismo , Sequência de Bases , Brônquios/metabolismo , Linhagem Celular , Proliferação de Células , Primers do DNA/genética , Bases de Dados Genéticas , Humanos , Metaloproteinase 10 da Matriz , Metaloendopeptidases/genética , Metaloendopeptidases/metabolismo , Análise de Sequência com Séries de Oligonucleotídeos , Transdução de Sinais , Inibidor Tecidual de Metaloproteinase-3/genética , Inibidor Tecidual de Metaloproteinase-3/metabolismoRESUMO
G protein-coupled receptor 154 (GPR154) is a recently discovered asthma susceptibility gene upregulated in the airways of asthma patients. We previously observed increased pulmonary mRNA expression of the murine ortholog Gpr154 in a mouse model of ovalbumin (OVA)-induced inflammation. However, the expression profile of GPR154 in leukocytes and the cellular functions of the receptor and its endogenous agonist neuropeptide S (NPS) have remained unidentified. Here, we characterized the mRNA expression of NPS and GPR154 by using real-time RT-PCR in fractionated human blood cells and in peripheral blood mononuclear cells (PBMCs) with monocyte or T cell activation. The expression of GPR154 in leukocytes was further confirmed by immunoblotting experiments and immunohistochemical staining of human sputum samples. Additionally, we characterized the expression of GPR154 in the lung tissue samples and in the bronchoalveolar lavage (BAL) fluid of OVA sensitized and challenged BALB/c mice. In human blood and sputum cells, monocyte/macrophages and eosinophils were identified as GPR154-positive cells. In PBMCs, monocyte activation with LPS but not T cell activation with anti-CD3/CD28 antibodies resulted in increased NPS and GPR154 expression. In the lung tissue samples and in the BAL fluid of OVA-challenged mice, GPR154 expression was upregulated in alveolar macrophages in comparison to controls. In the mouse macrophage RAW 264.7 cell line, NPS-stimulated Galphas- and Galphaq-dependent phagocytosis of Escherichia coli. The results show that GPR154 is upregulated in macrophages after antigen challenge and that NPS is capable of inducing phagocytosis of unopsonized bacteria.
Assuntos
Leucócitos Mononucleares/metabolismo , Macrófagos/imunologia , Neuropeptídeos/imunologia , Receptores Acoplados a Proteínas G/imunologia , Animais , Bronquite/imunologia , Líquido da Lavagem Broncoalveolar/imunologia , Antígenos CD28/imunologia , Complexo CD3/imunologia , Linhagem Celular , Eosinófilos/imunologia , Escherichia coli/imunologia , Escherichia coli/fisiologia , Feminino , Humanos , Técnicas In Vitro , Lipopolissacarídeos/toxicidade , Pulmão/metabolismo , Ativação Linfocitária , Macrófagos/microbiologia , Camundongos , Camundongos Endogâmicos BALB C , Fagocitose/imunologia , Escarro/metabolismoRESUMO
We recently identified a novel positional asthma susceptibility gene, GPRA, which belongs to the G protein-coupled receptor family. In the present studies, we show that isoform specific activation of GPRA-A with its agonist, Neuropeptide S (NPS) resulted in significant inhibition of cell growth. GPRA has several variants due to extensive alternative splicing. We observed that only the full-length variants, GPRA-A and GPRA-B, with 7 transmembrane topology are transported into the plasma membrane, while the truncated proteins retain intracellular compartments. To clarify disease mechanism, we studied co-expression of the variants without finding any indication that truncated variants would inhibit the receptor transport into the plasma membrane. By using in situ hybridization and immunohistochemistry, we detected ubiquitous expression of GPRA-B, and frequent expression of GPRA-A in the epithelia of several organs including bronchi and gastrointestinal tract. Furthermore, we observed aberrant mRNA and protein expression levels of GPRA in the asthmatic bronchi. Finally, we demonstrate that GPRA and NPS are co-expressed in bronchial epithelium. In summary, this study provides evidence that GPRA might have functional relevance in modulating asthma by increased expression levels in the relevant tissues under diseased state and by potential inhibitory effect of GPRA-A activation on cell growth.
Assuntos
Asma/genética , Asma/fisiopatologia , Receptores Acoplados a Proteínas G/genética , Sequência de Aminoácidos , Animais , Especificidade de Anticorpos , Células COS , Divisão Celular/fisiologia , Linhagem Celular Tumoral , Chlorocebus aethiops , Expressão Gênica/imunologia , Humanos , Imuno-Histoquímica , Hibridização In Situ , Neoplasias Pulmonares , Dados de Sequência Molecular , Neuropeptídeos/genética , Splicing de RNA , Receptores Acoplados a Proteínas G/imunologia , Receptores Acoplados a Proteínas G/metabolismo , Mucosa Respiratória/citologia , Transdução de Sinais/fisiologia , TransfecçãoRESUMO
BACKGROUND: We have shown that inhalation of leukotriene (LT) E 4 contributes to specific recruitment of eosinophils to the airway mucosa in patients with asthma at the time of maximal decrease in airway-specific conductance. OBJECTIVE: We examined the ability of the cysteinyl LT 1 receptor antagonist, zafirlukast, to improve or prevent LT-mediated eosinophilia and airway obstruction in asthma. METHODS: Bronchial biopsies were taken and pulmonary function was measured before and 4 to 6 hours after the dose of inhaled LTE 4 causing a > or =15% fall in FEV 1 at baseline both at week 0 and after 6-week randomly assigned treatment with a high dose of zafirlukast, 80 mg twice daily. RESULTS: Leukotriene E 4 inhalation at week 0 doubled the number of eosinophils in the airway mucosa in 21 of 25 patients with mild asthma, increased the numbers of neutrophils and lymphocytes, and decreased FEV 1 (-17%). Zafirlukast reduced both airway eosinophilia and obstruction in FEV 1 , whereas with a double-blind placebo treatment, the effect of LTE 4 on both parameters persisted for 6 weeks. On repeat LTE 4 inhalation challenge after 6 weeks, zafirlukast treatment prevented further airway eosinophilia and decrease in FEV 1 seen in the placebo group. CONCLUSION: Persistent LTE 4 -induced airway eosinophilia may form the basis of an amplification mechanism for further eosinophil recruitment. Zafirlukast prevents LTE 4 -induced eosinophilic airway inflammation in mild asthma.
Assuntos
Obstrução das Vias Respiratórias/tratamento farmacológico , Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Eosinofilia/tratamento farmacológico , Antagonistas de Leucotrienos/uso terapêutico , Leucotrieno E4/administração & dosagem , Compostos de Tosil/uso terapêutico , Administração por Inalação , Adulto , Obstrução das Vias Respiratórias/induzido quimicamente , Asma/fisiopatologia , Testes de Provocação Brônquica , Método Duplo-Cego , Eosinofilia/induzido quimicamente , Feminino , Volume Expiratório Forçado , Humanos , Indóis , Pulmão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Fenilcarbamatos , SulfonamidasRESUMO
BACKGROUND: Immune responses characterized by T H 2 type cells and IgE are important for the development of asthma and atopy. The transcription factors STAT6, GATA3, and STAT4 mediate the cytokine-induced development of naive CD4 + T cells into either T H 1 or T H 2 type. OBJECTIVE: We studied genetic variation of the STAT6, GATA3, and STAT4 genes and examined whether single nucleotide polymorphisms (SNPs) in these loci were associated with asthma or serum high IgE levels in the Finnish asthmatic families. METHODS: With denaturing high-performance liquid chromatography we screened all exons and exon-intron boundaries of the genes in 14 to 22 patients. All identified SNPs were genotyped in 120 nuclear families, and the haplotypes were analyzed by Haplotype Pattern Mining based statistical analysis. When potential association was observed, the analysis was replicated among 245 asthmatic patients and 405 population-based control subjects. RESULTS: A total of 23 SNPs were identified, of which 8 were not previously listed in the SNP database. Interestingly, a haplotype analysis of GATA3 showed 3 related haplotypes that associated with different asthma and atopy related phenotypes among both the family and case-control data sets. For STAT6 and STAT4, no significant association to asthma or serum total IgE levels was observed. CONCLUSIONS: We identified a panel of novel SNPs in genes coding for proteins important in the T H 1/T H 2 cell differentiation. SNPs of the GATA3 gene showed an initial association to asthma-related phenotypes. Elucidation of the importance of the identified panel of SNPs in other T H 1/T H 2 mediated diseases will be of great interest.
Assuntos
Asma/genética , Proteínas de Ligação a DNA/genética , Imunoglobulina E/sangue , Polimorfismo de Nucleotídeo Único , Transativadores/genética , Adulto , Asma/sangue , Asma/epidemiologia , Estudos de Casos e Controles , Estudos de Coortes , Finlândia/epidemiologia , Fator de Transcrição GATA3 , Genótipo , Haplótipos , Humanos , Pessoa de Meia-Idade , Fenótipo , Fator de Transcrição STAT4 , Fator de Transcrição STAT6 , Transdução de Sinais/genéticaAssuntos
Androstadienos/administração & dosagem , Asma/tratamento farmacológico , Asma/fisiopatologia , Hiper-Reatividade Brônquica/tratamento farmacológico , Administração por Inalação , Adolescente , Adulto , Hiper-Reatividade Brônquica/diagnóstico , Criança , Pré-Escolar , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Finlândia , Fluticasona , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Valores de Referência , Medição de Risco , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
Susceptibility to asthma depends on variation at an unknown number of genetic loci. To identify susceptibility genes on chromosome 7p, we adopted a hierarchical genotyping design, leading to the identification of a 133-kilobase risk-conferring segment containing two genes. One of these coded for an orphan G protein-coupled receptor named GPRA (G protein-coupled receptor for asthma susceptibility), which showed distinct distribution of protein isoforms between bronchial biopsies from healthy and asthmatic individuals. In three cohorts from Finland and Canada, single nucleotide polymorphism-tagged haplotypes associated with high serum immunoglobulin E or asthma. The murine ortholog of GPRA was up-regulated in a mouse model of ovalbumin-induced inflammation. Together, these data implicate GPRA in the pathogenesis of atopy and asthma.
Assuntos
Asma/genética , Cromossomos Humanos Par 7/genética , Predisposição Genética para Doença , Haplótipos , Receptores Acoplados a Proteínas G/genética , Algoritmos , Processamento Alternativo , Animais , Asma/metabolismo , Brônquios/química , Brônquios/citologia , Células Epiteliais/química , Feminino , Finlândia , Expressão Gênica , Genes , Ligação Genética , Variação Genética , Genótipo , Humanos , Hipersensibilidade/genética , Hipersensibilidade/metabolismo , Imunoglobulina E/sangue , Inflamação/genética , Pulmão/metabolismo , Masculino , Camundongos , Miócitos de Músculo Liso/química , Polimorfismo de Nucleotídeo Único , Quebeque , Receptores Acoplados a Proteínas G/análiseRESUMO
BACKGROUND: Salmeterol (SLM) is a long-acting beta(2)-receptor agonist that produces bronchodilatation for 12 hours in asthmatic subjects. The effects of the regular use of long-acting beta(2)-agonists on airway inflammation are largely unknown. OBJECTIVES: We examined the effects of 16 weeks of treatment with 50 microg SLM bid, 250 microg fluticasone propionate (FP) bid,5 mg disodium cromoglycate (DSCG) qid, or placebo on airway inflammation in bronchial mucosa. METHODS: Airway inflammation was assessed in bronchial biopsy specimens before and after treatments and bronchial hyperresponsiveness (BHR) in 80 patients with newly diagnosed asthma. Inflammatory cells and tenascin in the basement membrane were studied with immunohistochemical methods. Peak expiratory flow rate (PEF), symptoms, and need for rescue medication were recorded. RESULTS: SLM, FP, and DSCG reduced symptoms and need for rescue medication (P <.04). Both SLM and FP improved PEF and increased PD15FEV(1) to histamine by 2.8 and 5.2 doubling dose units, respectively. Both compounds reduced BHR more than placebo (P <.05). Both SLM and placebo had no effect on any inflammatory cell type. In both FP-treated and DSCG-treated patients, the number of EG2-positive eosinophils in the airway mucosa decreased (P =.002 and P <.05, respectively). CONCLUSIONS: SLM showed no anti-eosinophil properties in this study, but it provided good symptom control. FP provided the best anti-eosinophil properties and symptom relief of the studied compounds.
Assuntos
Obstrução das Vias Respiratórias/tratamento farmacológico , Albuterol/análogos & derivados , Albuterol/uso terapêutico , Androstadienos/uso terapêutico , Asma/tratamento farmacológico , Cromolina Sódica/uso terapêutico , Eosinófilos/efeitos dos fármacos , Adulto , Asma/patologia , Asma/fisiopatologia , Biópsia , Brônquios/patologia , Método Duplo-Cego , Eosinófilos/fisiologia , Feminino , Fluticasona , Humanos , Pulmão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Xinafoato de SalmeterolRESUMO
We have compared data from northern and southern Finland in a large epidemiological survey on respiratory conditions. The aim was to compare the prevalence of respiratory symptoms, asthma, and chronic bronchitis in northern and southern Finland. The study was a part of comparative studies in Finland, Estonia, and Sweden, the FinEsS studies. Data from a postal survey on subjects aged 20-69 was analyzed. Participation rate was 84% of 7937 invited in Lapland in the north, and 77% of 7877 in Helsinki in the south. Physician-diagnosed asthma was reported by 5.6% in Helsinki, and by 5.5% in Lapland. Symptoms common in asthma were also equally prevalent in the two areas. Hay fever was significantly more common in Helsinki, 36% vs. 26% (p < 0.001). The prevalence for physician-diagnosed chronic bronchitis was not significantly higher in Helsinki (3.4%) than in Lapland (2.9%). Those working outdoors reported more bronchitic symptoms than people working indoors (p < 0.05). Respiratory symptoms provoked by pollen or animal dander were more common in Helsinki, while symptoms provoked by inhaled irritants or cold weather conditions were more prevalent in Lapland. Current smoking was equally prevalent: 37% in Lapland and 38% in Helsinki. Risk factor analysis showed an elevated risk for chronic productive cough for living in Helsinki (OR 1.32), however, increasing age and current smoking were the strongest risk factors. In conclusion, prevalence of asthma and asthma-related symptoms was similar in southern and northern Finland, but chronic bronchitis and bronchitic symptoms were more common in Helsinki, and the highest prevalence was found among current smokers working outdoors. Respiratory symptoms in cold weather were more prevalent in the north, while hay fever and respiratory symptoms provoked by allergens were more common in the south. The results support the view that environmental factors have a substantial effect on respiratory symptoms, but less effect on the prevalence of asthma.
Assuntos
Alérgenos , Asma/epidemiologia , Clima Frio , Irritantes , Adulto , Idoso , Asma/diagnóstico , Tosse , Feminino , Finlândia/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Ocupações , Prevalência , Sons Respiratórios , Fatores de Risco , Fumar/epidemiologiaRESUMO
Chromosome 7p15-p14 showed genome-wide significant linkage to asthma related traits among the Finnish and French-Canadian families. As an essential step toward cloning the susceptibility gene, a detailed physical map of the region is needed. In this study we report a dense set of carefully tested, new microsatellite markers for fine mapping embedded in a continuous, easy-to-read, physical map of the region that includes the known genes and putative transcripts. Even though susceptibility genes for asthma are difficult to predict from a multitude of unknown genes mapped to the region, TCRG encoding the gamma-chain of the heterodimeric gamma/delta T cell receptor is a potential candidate. We present linkage and association results for TCRG in two independent Finnish family sets by using four highly polymorphic microsatellites spanning 169 kb across the locus. Linkage results confirmed our previous findings, but our study did not provide any evidence on behalf of a strong association of TCRG with either high serum total Immunoglobulin (IgE) level or asthma. Our results suggest that some other known or yet unidentified gene in the linkage region is the true asthma susceptibility gene.
Assuntos
Asma/genética , Cromossomos Humanos Par 7 , Predisposição Genética para Doença , Mapeamento Físico do Cromossomo , Receptores de Antígenos de Linfócitos T/genética , Marcadores Genéticos , Humanos , Repetições de MicrossatélitesRESUMO
The effects of two angiotensin I convening enzyme inhibitors on the kallikrein-kinin system and prostanoids were studied in spontaneously hypertensive rats. The doses of captopril were 20, 50 and 100 mg/kg×day given twice daily, and those of CI-906 20 and 40 mg/kg once daily. Both drugs were equally effective in reducing the systolic blood pressure. Captopril increased urine volume dose-dependently (up to 3-fold with the largest dose). Only the larger dose of CI-906 was slightly diuretic. Captopril decreased the 24-h urinary excretion of kallikrein, while the excretion of the prostacyclin metabolite 6-keto-PGF1α was increased markedly and that of T × B2 to a lesser extent. CI-906 had no effect on the 24-h urinary excretion of kallikrein, 6-keto-PGF1α and T × B2. Both drugs tended to reduce PGE2 excretion. Captopril and CI-906 did not alter plasma kininogen levels. The marked renal effects of captopril may be caused by a strong local inhibition of converting enzyme in the kidneys. Captopril is mainly excreted unchanged in urine, and it is secreted actively by the proximal tubular cells. CI-906 is eliminated predominantly by biliary excretion. It is also possible that direct stimulation of prostacyclin formation by captopril may be involved in the diuretic action of the drug. However, as it was shown with CI-906, the increase in urine flow and the associated changes in urinary kallikrein and prostanoids are not necessary for the antihypertensive effect caused by the inhibition of converting enzyme.